Skip to content
Ecat.nl
Ecat.nl
Home
Docs
Surveys and Studies
Emicizumab pilot study, part II
Emicizumab pilot study, part II
In Newsletter 20 of June 2021 P. Meijer described Emicizumab pilot study, part II
Related items
Analytical Information :
9
A computer-based model to access costs associated with the use of factor VIII and factor IX one-stage and chromogenic activity assay
Minimum citrate tube fill volume for routine coagulation testing
Interference of rivaroxaban in one-stage and chromogenic factor VIII:C assays
The responsiveness of different APTT reagents to mild factor VIII, IX and XI deficiencies
Results of a workshop on the inter-laboratory variability of analysis of type 1 factor VIII Inhibitors
The do’s and don’ts of laboratory detection of haemostasis-inhibitors: lessons from a workshop
Comparison of two statistical software programs for determining reference intervals of screening coagulation assays
Analytical performance specifications for hemostasis parameters
The effect of Rivaroxaban on haemostasis assays; results from ECAT surveys
Cases :
11
Prekallikrein deficiency
Effect of high haematocrit levels on coagulation testing
A patient with acquired factor X deficiency and metastatic carcinoma of the bladder: is there a link between metastasis and factor deficiency in solid tumours?
A patient with mild haemophilia A
Acquired factor X deficiency
Lupus Anticoagulant-Hypoprothrombinemia Syndrome
Haemophilia B and treatment, case study
Haemophilia A and treatment, case study
A severe haemophilia A patient treated with emicizumab, case study
Acquired haemophilia A
Acquired Hemophilia A, case study
Guidelines :
3
ICSH recommendations for the performance and interpretation of activated partial thromboplastin time and prothrombin time mixing tests
Field Study Evaluating Optimal Interpretation Methods for Activated Partial Thromboplastin Time and Prothrombin Time Mixing Studies
Recommendations for laboratory measurement of factor VIII and FIX type I inhibitors, ICSH recommendations
Haemostatic Cascade :
6
TF Pathway (Extrinsic) with Common Pathway (PT)
Intrinsic Pathway APTT
Coagulation Pathways (All Components)
Activation of TAFI by Thrombin
Activation of Protein C by Thrombin
Activation of Platelets by Thrombin
Quality Issues :
4
Biological Variation of Hemostasis Variables in Thrombosis and Bleeding: Consequences for Performance Specifications
Quality Assurance of replacement therapy and future perspectives
External quality assessment for Factor VIII and Factor IX
The between-laboratoy variation of Factor VIII inhibitor testing
Surveys and Studies :
2
Emicizumab pilot study, part I
Performance of factor IX extended half-life product measurements in external quality control assessment programs
Questions or suggestions?
Clotpedia Support Form
Submit
Success
